We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Capping Laboratory Diagnostics Strategy, Siemens to Acquire Dade Behring for $7 Billion

By HospiMedica staff writers
Posted on 30 Jul 2007
Print article
Further building on its bold quest for global leadership in the dynamic in-vitro diagnostics sector, initiated with its recent acquisitions of Bayer Diagnostics and DPC, Siemens Medical Solutions has agreed to buy Dade Behring for about US$7 billion. Subject to regulatory approvals, the transaction is expected to close by March 2008.

With annual revenues of about $1.7 billion and some 6,400 employees in 35 countries, Dade Behring (Deerfield, IL, USA) is a global leader in laboratory diagnostics, including clinical chemistry testing, immunodiagnostics, hemostasis testing, and microbiology.

Siemens Medical Solutions (Erlangen, Germany), one of the world's largest providers of healthcare products and systems, and a unit of technology giant Siemens AG (Munich, Germany), employs more than 41,000 people in some 130 countries and reported sales of EUR 8.23 billion in fiscal 2006.

With the proposed acquisition, Siemens Medical Solutions aims at advancing its vision of becoming the global leader in full-range medical diagnostics – incorporating imaging diagnostics, clinical laboratory diagnostics, and healthcare information technology (IT) – all offered from a single source and under the Siemens umbrella.

Erich R. Reinhardt, president of Siemens Medical Solutions, pointed out, the planned acquisition of Dade Behring complements our current capabilities and offers us the unique opportunity to create an unparalleled portfolio of products and services, and become world market leader in comprehensive clinical laboratory diagnostics.

Siemens' foray into the relatively fast-growing and high-margin laboratory diagnostics field was first launched in mid-2006, when Diagnostics Products Corp. (DPC), a major player in immunodiagnostics, was acquired for $1.86 billion. This was soon followed with Siemens agreeing to buy Bayer AG's diagnostics division for EUR 4.2 billion. The acquisition of Bayer Diagnostics - with 2006 sales exceeding EUR 1.5 billion – elevated Siemens' emerging laboratory diagnostics group to the top ranks of the industry, a position to be further enhanced with the proposed acquisition.


A 'homecoming' for the venerable Behring imprint

Dade Behring was formed in 1997 by the merger of two venerable names from across two continents – Behring Diagnostics, founded in 1904 in Marburg, Germany, by the legendary scientist Dr. Emil Behring; and Dade International, founded in 1949 in Miami, FL, USA, by blood bank pioneer Dr. John Elliott.

Considered the father of modern immunology and serology, Dr. Behring discovered the diphtheria antitoxin and brought about other breakthroughs related to infectious diseases, earning him the first Nobel Prize for Medicine in 1901. Behringwerke, founded by Dr. Behring in the university town of Marburg to commercialize his scientific developments, expanded into diagnostic products in 1935 and ever since formed a pillar of the laboratory diagnostics sector in Germany.

Industry sources commented that Siemens might be paying a premium for
bringing the illustrious Behring name back home. In its claim for
global leadership, they expect Siemens' newly-minted laboratory
diagnostics powerhouse to fully capitalize on the value of the Behring
image.


GE's proposed Abbott Diagnostics acquisition is called off

The benefits of merging in-vitro (laboratory) and in-vivo (imaging) diagnostics under one roof, did not go unnoticed by GE Healthcare (Chalfont St. Giles, UK), a principal Siemens rival in the global healthcare sector. Accordingly, in January 2007, GE Healthcare initiated an agreement to buy market leader Abbott Laboratories' in-vitro and point-of-care (POC) diagnostics segment – a business that showed sales of $2.7 billion in 2006 – for $8.13 billion. However, the financial community was displeased with what it viewed as an excessive price tag, while ongoing regulatory problems in the manufacturing area raised additional hurdles. As a result, the proposed acquisition was called off in mid-July.


Related Links:
Siemens Medical Solutions
Dade Behring
GE Healthcare
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Diagnostic Ultrasound System
MS1700C
New
Computed Tomography System
Aquilion ONE / INSIGHT Edition

Print article

Channels

Surgical Techniques

view channel
Image: The new treatment combination for subdural hematoma reduces the risk of recurrence (Photo courtesy of Neurosurgery 85(6):801-807, December 2019)

Novel Combination of Surgery and Embolization for Subdural Hematoma Reduces Risk of Recurrence

Subdural hematomas, which occur when bleeding happens between the brain and its protective membrane due to trauma, are common in older adults. By 2030, chronic subdural hematomas are expected to become... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.